WHO grants emergency approval to 2nd Chinese COVID vaccine

The organization approved the vaccine made by Sinovac for adults 18 and over.

A+healthcare+worker+prepares+a+dose+of+the+Sinovac+COVID-19+vaccine+during+a+vaccination+session+for+medical+staff+who+work+at+private+clinics+in+Caracas%2C+Venezuela+on+May+28.

MATIAS DELACROIX/Associated Press

A healthcare worker prepares a dose of the Sinovac COVID-19 vaccine during a vaccination session for medical staff who work at private clinics in Caracas, Venezuela on May 28.

Associated Press

GENEVA, Switzerland — The World Health Organization has issued an emergency use listing for the COVID-19 vaccine made by Sinovac for adults 18 and over, the second such authorization it has granted to a Chinese company.

In a statement Tuesday, the U.N. health agency said data submitted to its experts showed that two doses of the vaccine prevented people from getting symptoms of COVID-19 in about half of those who got the vaccine. WHO said few older adults enrolled in the research, so it could not estimate how effective the vaccine was in people over 60.

“Nevertheless, WHO is not recommending an upper age limit for the vaccine,” the agency said, adding that data collected from Sinovac’s use in other countries “suggest the vaccine is likely to have a protective effect in older persons.”

In April, scientists published a study in Brazil confirming the previously reported efficacy rate of over 50% for Sinovac. A real-world study in Chile in April found an efficacy rate of 67%.

Last month, WHO gave the green light to the COVID-19 vaccine made by Sinopharm. It has also licensed vaccines developed by Pfizer-BioNTech, AstraZeneca, Moderna and Johnson & Johnson.

WHO’s authorization means donors and other U.N. agencies can buy the vaccine for use in poorer countries, including in the U.N.-backed initiative to distribute COVID-19 vaccines globally known as COVAX. The effort has slowed considerably after its biggest supplier in India said it would not provide any more vaccines until the end of the year because of the latest surge of new infections now ravaging India.

To date, there is no confirmed deal for Sinovac doses with COVAX.

In May, Europe’s drug regulator began an expedited review process for the Sinovac vaccine, but it’s unclear when a decision might be made about its possible authorization for the 27-nation bloc.

Hundreds of millions of Chinese vaccines have already been delivered to dozens of countries worldwide through bilateral deals, as many nations scrambled to secure supplies after rich countries reserved the vast majority of supplies from Western pharmaceutical makers.

While China has five vaccine shots in use, most of its exports are manufactured by two companies: Sinopharm and Sinovac. The Chinese vaccines are “inactivated” vaccines, made with killed coronavirus.

Most other COVID-19 vaccines being used around the world, particularly in the West, are made with newer technologies that instead target the “spike” protein that coats the surface of the coronavirus.

(Visited 10 times, 1 visits today)